265 related articles for article (PubMed ID: 23584313)
1. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization.
Berland DW; Malinoff HL; Weiner MA; Przybylski R
Am J Ther; 2013; 20(4):316-21. PubMed ID: 23584313
[TBL] [Abstract][Full Text] [Related]
2. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.
Daitch D; Daitch J; Novinson D; Frey M; Mitnick C; Pergolizzi J
Pain Med; 2014 Dec; 15(12):2087-94. PubMed ID: 25220043
[TBL] [Abstract][Full Text] [Related]
5. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec) in post-traumatic pain.
Correa-Illanes G; Roa RG; B Piñeros JL; Ferrer FT; Adriasola VR
Pain Manag; 2014 May; 4(3):181-90. PubMed ID: 24835268
[TBL] [Abstract][Full Text] [Related]
7. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
[TBL] [Abstract][Full Text] [Related]
8. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
Likar R; Kayser H; Sittl R
Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine transdermal system utilization.
Wallace L; Kadakia A
Postgrad Med; 2017 Jan; 129(1):81-86. PubMed ID: 27901359
[TBL] [Abstract][Full Text] [Related]
10. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
Griessinger N; Sittl R; Likar R
Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone.
Ling W; Hillhouse M; Jenkins J; Miotto K; Torrington M; Chapleo C
J Addict Med; 2012 Jun; 6(2):118-23. PubMed ID: 22475985
[TBL] [Abstract][Full Text] [Related]
12. Transdermal buprenorphine controls central neuropathic pain.
Weiner M; Sarantopoulos C; Gordon E
J Opioid Manag; 2012; 8(6):414-5. PubMed ID: 23264319
[TBL] [Abstract][Full Text] [Related]
13. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
[TBL] [Abstract][Full Text] [Related]
14. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
[TBL] [Abstract][Full Text] [Related]
16. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
18. Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study.
Gallagher AM; Leighton-Scott J; van Staa TP
Clin Ther; 2009 Aug; 31(8):1707-15. PubMed ID: 19808129
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine for chronic pain.
Calderon R; Copenhaver D
J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):402-5. PubMed ID: 24245573
[TBL] [Abstract][Full Text] [Related]
20. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G
Curr Med Res Opin; 2014 Aug; 30(8):1579-87. PubMed ID: 24689806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]